| Inclusion criteria | Male and female adult patients, ages 18–80 years, prescribed TRAM/DKP FDC for moderate to severe acute pain. Patients willing to give consent for the study.
|
| Exclusion criteria | Hypersensitivity to dexketoprofen, to any other NSAID, or to any of the excipients. Patients in whom substances with a similar action (eg, acetylsalicylic acid or other NSAIDs) precipitate attacks of asthma, bronchospasm, acute rhinitis or cause nasal polyps, urticaria or angioneurotic oedema. Known photo allergic or phototoxic reactions during treatment with ketoprofen or fibrates. Patients with active peptic ulcer/gastrointestinal haemorrhage or any history of gastrointestinal bleeding ulceration or perforation. Patients with history of gastrointestinal bleeding or perforation, related to previous NSAIDs therapy. Patients with chronic dyspepsia. Patients who have other active bleeding or bleeding disorders. Patients with Crohn’s disease or ulcerative colitis. Patients with a history of bronchial asthma (even if not drug induced). Patients with severe heart failure. Patients with moderate to severe renal dysfunction (creatinine clearance <59 mL/min). Patients with severely impaired hepatic function (Child-Pugh C). Patients with haemorrhagic diathesis and other coagulation disorders. Patients with severe dehydration (caused by vomiting, diarrhoea or insufficient fluid intake). Hypersensitivity to tramadol or to any of the excipients. Acute intoxication with alcohol, hypnotics, analgesics, opioids or psychotropic medicinal products. Patients receiving MAO inhibitors or who have taken them within the last 14 days. Patients with epilepsy not adequately controlled by treatment. Severe respiratory depression. Pregnancy and lactation.
|